ImmunityBio/IBRX

$4.73

-3.09%
-
1D1W1MYTD1YMAX

About ImmunityBio

Immunitybio, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing therapies and vaccines that improve the immune system to defeat cancers and infectious diseases. Its segment is focused on creating the next generation of immunotherapies to address serious unmet needs within oncology and infectious diseases. Its platforms include antibody cytokine fusion proteins; DNA, RNA, and recombinant protein vaccine technologies, including self-amplifying RNA, second-generation adenovirus hAd5 vector and recombinant protein platforms; toll-like receptor activating adjuvants; natural killer (NK) cell therapy, including off-the-shelf NK cells, and autologous and allogenic memory-like cytokine-enhanced NK cells (M-ceNK); damage-associated molecular patterns inducers, including Aldoxorubicin and Nanatinostat. Its clinical pipeline consists of over 26 clinical trials of which 17 are in Phase I or III development, across 13 indications in liquid and solid tumors.
Ticker
IBRX
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology & Drugs
CEO
Patrick Soon-Shiong
Employees
683
Headquarters
San diego, United States

ImmunityBio Metrics

BasicAdvanced
$3.24B
Market cap
-
P/E ratio
-$1.05
EPS
1.08
Beta
-
Dividend rate

What the Analysts think about ImmunityBio

Analyst Ratings

Majority rating from 1 analysts.
Hold

Price Targets

Average projection from 2 analysts.
4.86% downside
High $5.00
Low $4.00
$4.73
Current price
$4.50
Average price target

ImmunityBio Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$0
-
Net income
$-95.5M
-30.7%
Profit margin
0%
-

ImmunityBio Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 25.49%
QuarterlyAnnual
Q4 22
Q2 23
Q3 23
Q4 23
Actual
-$0.27
-$0.32
-$0.19
-
Expected
-$0.22
-$0.24
-$0.26
-$0.18
Surprise
22.73%
36.17%
-25.49%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell ImmunityBio stock

Buy or sell ImmunityBio stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing